Determining the concentrations of the squamous cell carcinoma antigen using the Maglumi 2000 automatic analyzer

AIM

The aim of this paper was to validate the use of the chemiluminescence immunoassay (CLIA) for detecting the squamous cell carcinoma antigen (SCCa) in human serum or plasma using a Maglumi 2000 automatic analyzer.

METHODS

We performed a pilot study to examine both the sensitivity and specificity of the SCCa, in diagnosing squamous cell carcinomas. High levels of SCCa are helpful in diagnosing lung cancer, especially squamous cell carcinoma.

RESULTS

The method was linear to 22.81 ng/mL SCCa, with a detection limit of 0.02 ng/mL. An entire assay can be completed in 40 mins. The coefficients of variation (CV) of the intra- and inter-assays were less than 5% and 6%, respectively. There was a good correlation between the present and manual method. The SCCa discriminated between the squamous cell carcinoma patients and healthy controls with an area under the receiver operating characteristic (ROC) curve of 0.9231.

CONCLUSION

These results indicate that the SCCa assay showed good performance using a Maglumi 2000 automatic analyzer. This new and simple analytic system will promote the application of SCCa in clinical laboratories.

Association analysis of the IL2RA gene with alopecia areata in a Chinese population

BACKGROUND

Interleukin-2 receptor subunit alpha (IL2RA) is highly expressed on CD4+CD25+ regulatory T cells and is important for immune homeostasis and the suppression of autoimmune responses. It has been suggested that the single nucleotide polymorphism in IL2RA may affect the pathogenesis of alopecia areata (AA).

OBJECTIVE

Our aim was to investigate the link between IL2RA polymorphism and AA in a Chinese population.

METHODS

We examined 427 patients and 430 controls in this study. The rs3118470 polymorphism was evaluated using high-resolution melting analysis and direct sequencing.

RESULTS

The prevalence of the C/C, T/C and T/T genotypes was 16.2, 48.2 and 35.6%, respectively. The genotype distribution and allele frequencies were significantly different between AA and control subjects (p < 0.0001). The C allele frequency was significantly higher in the AA group (p < 0.0001), and the frequencies of C allele and C/C genotype were higher in the patients with family history (p = 0.034; p < 0.0001).

CONCLUSIONS

The rs3118470 single nucleotide polymorphism of IL2RA may be a genetic marker to assess the risk of AA in a Chinese population.

Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury

Acute vascular rejection (AVR) is characterized by immune-mediated vascular injury and heightened endothelial cell (EC) apoptosis. We reported previously that apoptotic ECs release a bioactive C-terminal fragment of perlecan referred to as LG3. Here, we tested the possibility that LG3 behaves as a neoantigen, fuelling the production of anti-LG3 antibodies of potential importance in regulating allograft vascular injury. We performed a case-control study in which we compared anti-LG3 IgG titers in kidney transplant recipients with AVR (n=15) versus those with acute tubulo-interstitial rejection (ATIR) (n=15) or stable graft function (n=30). Patients who experienced AVR had elevated anti-LG3 titers pre and posttransplantation compared to subjects with ATIR or stable graft function (p<0.05 for both mediators). Elevated pretransplant anti-LG3 titers (OR: 4.62, 95% CI: 1.08-19.72) and pretransplant donor-specific antibodies (DSA) (OR 4.79, 95% CI: 1.03-22.19) were both independently associated with AVR. To address the functional role of anti-LG3 antibodies in AVR, we turned to passive transfer of anti-LG3 antibodies in an animal model of vascular rejection based on orthotopic aortic transplantation between fully MHC-mismatched mice. Neointima formation, C4d deposition and allograft inflammation were significantly increased in recipients of an ischemic aortic allograft passively transferred with anti-LG3 antibodies. Collectively, these data identify anti-LG3 antibodies as novel accelerators of immune-mediated vascular injury and obliterative remodeling.

Differential expression of serine-threonine kinase receptor-associated protein in patients with systemic lupus erythematosus

The serine-threonine kinase receptor-associated protein (STRAP), a 39 kDa protein localized predominantly in cytoplasm, is an important inhibitor of transforming growth factor beta (TGF-ß) signaling and a regulator of cell proliferation. To investigate the application of STRAP as a novel biomarker in evaluating the pathological condition of systemic lupus erythematosus (SLE), and to determine the possible involvement of STRAP in SLE pathogenesis, the expression levels of STRAP in peripheral blood mononuclear cells (PBMC) of SLE patients were analyzed. PBMC were collected from six patients with active SLE, six with stable SLE and six healthy controls; after protein extraction and concentration determination, the samples were labeled with reagents for isobaric tagging for relative and absolute protein quantification (iTRAQ) and detected by tandem mass spectrometry. The initial proteomic analysis identified and quantified hundreds of proteins. Of these, STRAP was found to decrease more than three-fold in active SLE patients compared with healthy controls (the relative ratio was 0.291). The under-expression of STRAP in active SLE was further verified by western blot in larger independent sample sets. Clinical data analyses revealed that the levels of STRAP in SLE inversely correlated to the SLE disease activity index (SLEDAI) (r = -0.607, p < 0.05). These results indicate that the under-expression of STRAP may be a negative factor in the pathogenic process of SLE; as a result, this may also be of clinical significance as a potential condition-specific indicator of active SLE.

A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women

We hypothesized that exemestane (EXE) would reduce mammographic breast density and have unique effects on biomarkers of bone and lipid metabolism. Healthy postmenopausal women were randomized to EXE (25 mg daily) or placebo (PLAC) for 12 months and followed for a total of 24 months. The primary endpoint was change in percent breast density (PD) between the baseline and 12-month mammograms and secondary endpoints were changes in serum lipid levels, bone biomarkers, and bone mineral density (BMD). Ninety-eight women were randomized (49 to EXE; 49 to PLAC) and 65 had PD data at baseline and 12 months. Among women treated with EXE, PD was not significantly changed from baseline at 6, 12, or 24 months and was not different from PLAC. EXE was associated with significant percentage increase from baseline in N-telopeptide at 12 months compared with PLAC. No differences in percent change from baseline in BMD (lumbar spine and femoral neck) were observed between EXE and PLAC at either 12 or 24 months. Patients on EXE had a significantly larger percent decrease in total cholesterol than in the PLAC arm at 6 months and in HDL cholesterol at 3, 6, and 12 months. No significant differences in percent change in LDL or triglycerides were noted at any time point between the two treatment arms. EXE administered for 1 year to healthy postmenopausal women did not result in significant changes in mammographic density. A reversible increase in the bone resorption marker N-telopeptide without significant change in bone specific alkaline phosphatase or BMD during the 12 months treatment period and 1 year later was noted. Changes in lipid parameters on this trial were modest and reversible.